Very Rare Cause of Cardiomyopathy in a Child: Peripartum Cardiomyopathy
Öz
Abstract.
Background: Peripartum cardiomyopathy (PCMP) is characterized by severe systolic dysfunction of the heart, manifesting with signs and symptoms of heart failure in the last month of pregnancy or within the first five months postpartum in women with no previously known heart disease. Methods: A childhood-age pregnancy mother who presented to our emergency department at 3 months postpartum with complaints of dyspnea, orthopnea, edema, and palpitations. Following the diagnosis of PCMP, standard cardiomyopathy treatment was initiated alongside bromocriptine therapy. However, during follow-up, the patient died due to heart failure. PCMP, which is rare even in adult patients, can also occur in the pediatric age group. The using bromocriptine, which pediatric cardiologists may be less familiar with, in addition to standard heart failure therapy is needed to cure it, but the nature of the disease could be very severe.
Anahtar Kelimeler
peripartum cardiomyopathy, bromocriptine, childhood pregnancy
Destekleyen Kurum
yok
Etik Beyan
Etik kurallara vaka sunumu sırasında uyulmuştur
Teşekkür
yayınlanması için değerlendirilmesine teşekkür ederim
Kaynakça
- 1. Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis, and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21:827-843.
- 2. Koziol KJ, Aronow WS. Peripartum cardiomyopathy: current understanding of pathophysiology, diagnostic workup, management, and outcomes. Curr Probl Cardiol. 2023; 48:101716.
- 3. Kayıkçıoğlu M, Biteker M, Mutluer FO, Güzel T, Yılmaz E, Demir E, et al. Baseline characteristics and clinical insights from the ARTEMIS registry: a comprehensive study of peripartum cardiomyopathy in Türkiye. Turk Kardiyol Dern Ars. 2024;52:474-83.
- 4. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121:1465-73.
- 5. Tremblay-Gravel M, Marquis-Gravel G, Avram R, Desplantie O, Ducharme A, Bibas L, et al. The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO-HF retrospective cohort study. ESC Heart Fail. 2019;6:27-36.
- 6. Yönem A, Kutlu M. Hyperprolactinemia: diagnosis and treatment. T Klinikleri J Med Sci. 1999;19:63-72.
- 7. van der Meer P, van Essen BJ, Viljoen C, Bohm M, Jackson A, Hilfiker-Kleiner D, et al. Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry. Eur Heart J. 2025;46:1017-27.
- 8. Boran P, Gökçay G, Devecioğlu E, Eren T. Child brides. Marmara Med J. 2013;26:52-58.
- 9. https://data.tuik.gov.tr/Kategori/GetKategori?p=nufus-ve-demografi-109&dil=1(last access data 17.02.2025).